Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Jul
30
Today In Oncology
Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Global Breast Cancer Survival Estimates: WHO Analysis
Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo